AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

Dow Jones

Feb 26, 2025

0804 GMT - The results of AstraZeneca's upcoming cancer drug trial have the potential to drive consensus forecasts toward the drug maker's 2030 sales target of $80 billion, Berenberg analysts say in a note. The British pharma company expects positive key late-stage trial readouts for its breast cancer drug Datroway, label extensions for its breast cancer drug Enhertu and hypertension treatment baxdrostat. The company guides for high-single-digit revenue growth but should face headwinds from patent expiries, U.S. Medicare drug pricing reform and foreign currency effects, they say. AstraZeneca's share price is back on track after its 2025 outlook eased investor concerns about the prospects for its China business, which is hampered by ongoing corruption investigation against some of its employees. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

February 26, 2025 03:04 ET (08:04 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514716000"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514716000\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514716000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 16:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514716000","market":"fut","top_or_hot":-1,"title":"AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0804 GMT - The results of AstraZeneca's upcoming cancer drug trial have the potential to drive consensus forecasts toward the drug maker's 2030 sales target of $80 billion, Berenberg analysts say in a note. The British pharma company expects positive key late-stage trial readouts for its breast cancer drug Datroway, label extensions for its breast cancer drug Enhertu and hypertension treatment baxdrostat. The company guides for high-single-digit revenue growth but should face headwinds from patent expiries, U.S. Medicare drug pricing reform and foreign currency effects, they say. AstraZeneca's share price is back on track after its 2025 outlook eased investor concerns about the prospects for its China business, which is hampered by ongoing corruption investigation against some of its employees. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2025 03:04 ET (08:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-26 16:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0804 GMT - The results of AstraZeneca's upcoming cancer drug trial have the potential to drive consensus forecasts toward the drug maker's 2030 sales target of $80 billion, Berenberg analysts say in a note. The British pharma company expects positive key late-stage trial readouts for its breast cancer drug Datroway, label extensions for its breast cancer drug Enhertu and hypertension treatment baxdrostat. The company guides for high-single-digit revenue growth but should face headwinds from patent expiries, U.S. Medicare drug pricing reform and foreign currency effects, they say. AstraZeneca's share price is back on track after its 2025 outlook eased investor concerns about the prospects for its China business, which is hampered by ongoing corruption investigation against some of its employees. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2025 03:04 ET (08:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514716000","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514716000","pubTimestamp":1740557040,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0804 GMT - The results of AstraZeneca's upcoming cancer drug trial have the potential to drive consensus forecasts toward the drug maker's 2030 sales target of $80 billion, Berenberg analysts say in a note. The British pharma company expects positive key late-stage trial readouts for its breast cancer drug Datroway, label extensions for its breast cancer drug Enhertu and hypertension treatment baxdrostat. The company guides for high-single-digit revenue growth but should face headwinds from patent expiries, U.S. Medicare drug pricing reform and foreign currency effects, they say. AstraZeneca's share price is back on track after its 2025 outlook eased investor concerns about the prospects for its China business, which is hampered by ongoing corruption investigation against some of its employees. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"阿斯利康的癌症药物产品线可能推动800亿美元的销售目标——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"0804 GMT - The results of AstraZeneca's upcoming cancer drug trial have the potential to drive consensus forecasts toward the drug maker's 2030 sales target of $80 billion, Berenberg analysts say in a note. The British pharma company expects positive key late-stage trial readouts for its breast cancer drug Datroway, label extensions for its breast cancer drug Enhertu and hypertension treatment baxdrostat. The company guides for high-single-digit revenue growth but should face headwinds from patent expiries, U.S. Medicare drug pricing reform and foreign currency effects, they say. AstraZeneca's share price is back on track after its 2025 outlook eased investor concerns about the prospects for its China business, which is hampered by ongoing corruption investigation against some of its employees. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 03:04 ET (08:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}